Q32 Bio reported new Phase 2 results for bempikibart (IL-7Rα inhibitor) in severe alopecia areata, and investors responded immediately. In part B of the SIGNAL-AA study, the company said bempikibart reduced disease severity scores, supporting its positioning as a non-JAK option aimed at improving efficacy while avoiding JAK-associated risks. The readout comes as Q32 seeks to broaden the non-JAK footprint in autoimmune skin disease, after earlier mixed outcomes in other indications. Analysts and market participants treated the latest efficacy confirmation as progress toward a potential mid-stage path where dosing durability and response depth could determine competitive placement. The company also disclosed a proposed $200 million public offering after the data release, linking clinical differentiation directly to near-term funding needs.